GHK-Cu + KPV + BPC-157 is a three-peptide vendor blend that adds the cytoprotective pentadecapeptide BPC-157 to the GHK-Cu + KPV pairing already covered in its own VialTalk monograph. Each component comes from a different literature: GHK-Cu from skin and matrix biology, KPV from anti-inflammatory melanocortin research, and BPC-157 from rodent tissue-repair work. The central limitation: the three-peptide combination has never been studied.
The blend contains three distinct peptides. GHK-Cu is glycyl-L-histidyl-L-lysine complexed with copper(II); the copper complex is the form most studied [1]. KPV is the tripeptide Lys-Pro-Val, the C-terminal fragment of α-melanocyte-stimulating hormone [2]. BPC-157 is a synthetic 15-amino-acid peptide derived from a fragment of a protein identified in human gastric juice [3]. VialTalk's catalog tracks this product as lyophilized vials, including one listed under the label "GHKCU + BPC-157 + KPV (70mg)". That label states a total only; the split between the three peptides is set by each vendor, is not standardised, and VialTalk does not reproduce per-component amounts. There is no single molecular formula for the blend.
GHK-Cu — matrix and copper biology. GHK-Cu acts as a copper-delivery vehicle for enzymes involved in connective-tissue formation and is reported to influence expression of many genes involved in tissue remodelling and to support collagen and matrix synthesis [1]. In zebrafish larvae, it reduced inflammatory-cell migration and pro-inflammatory cytokine expression, raised il-10, reduced reactive oxygen species and downregulated the JAK1 pathway [5].
KPV — inflammatory signalling. KPV is reported to retain the anti-inflammatory activity of α-MSH without the pigmentation effects [2]. In human bronchial epithelial cells, it inhibited NF-κB signalling and chemokine secretion, associated with nuclear import of KPV and suppressed nuclear translocation of the p65RelA subunit [6]. In a rat colitis model, hydrogel-delivered KPV alleviated colitis and supported epithelial-barrier recovery [7].
BPC-157 — vascular and cytoprotective repair. Reported mechanisms, still hypothesised, include VEGFR2-linked angiogenesis and nitric oxide modulation [3]; a 2025 review adds Akt-eNOS and ERK1/2 signalling and fibroblast activation [8]. In tendon fibroblasts, it increased survival under oxidative stress and cell migration, with FAK and paxillin activation [9].
The rationale for combining them. The existing GHK-Cu + KPV monograph frames that pair as a structural-remodelling layer plus an inflammatory-signalling layer [4]; adding BPC-157 adds an angiogenic and cytoprotective repair layer [3][8]. A 2026 review placing GHK-Cu and BPC-157 together describes both as tissue-repair peptides with largely preclinical evidence [10]. This layered framing is a vendor and community rationale; no study has tested it.
No study of this three-peptide combination was found. A PubMed search requiring all three names (GHK-Cu/glycyl-L-histidyl-L-lysine, KPV/Lys-Pro-Val and BPC-157) returned no records. Pairwise, the picture is no better: the only PubMed record naming both BPC-157 and KPV is a 2026 review of FDA compounding-committee evaluations, not an experiment [11]; records naming both GHK-Cu and BPC-157 are narrative or scoping reviews that treat each peptide separately [10][12]; and the GHK-Cu + KPV pairing likewise has no completed human trial [4].
Evidence tiers by component:
A 2026 sports-medicine scoping review concluded that claimed musculoskeletal benefits of emerging peptides, including BPC-157 and GHK-Cu, remain unsubstantiated by human trials [12]. Nothing is known about interaction among the three peptides, about co-formulation stability, or about whether the copper complex is affected by the other components.
This blend sits between the two-peptide GHK-Cu + KPV pair and four-peptide formulations that add TB-500 [4]. Researchers choosing between them should recognise that adding components multiplies untested interactions without adding combination evidence; none of these blends has been studied as a fixed formulation.
Store sealed lyophilized vials frozen or refrigerated, dry and protected from light. The blue colour from the GHK-Cu copper complex is expected [1]. Default to the most conservative storage window among the three components.
A meaningful COA must confirm identity of all three peptides by mass spectrometry and report HPLC purity for each, with a per-component content breakdown rather than a total-mass figure such as the vial label. For GHK-Cu, the COA should confirm the copper complex rather than bare GHK [1]; copper content is a useful addition [4]. BPC-157 sequence-incorrect and under-filled product is a known problem [3]. Single-line "peptide blend ≥98%" statements are effectively unverified [4]. Endotoxin and sterility data should be reported.
[1] VialTalk monograph — GHK-Cu — https://vialtalk.com/forum/peptide-research-library/ghk-cu-research-monograph-copper-tripeptide-skin-repair
[2] VialTalk monograph — KPV — https://vialtalk.com/forum/peptide-research-library/kpv-research-monograph-alpha-msh-tripeptide-anti-inflammatory
[3] VialTalk monograph — BPC-157 — https://vialtalk.com/forum/peptide-research-library/bpc-157-research-monograph-structure-mechanism-evidence
[4] VialTalk monograph — GHK-Cu + KPV — https://vialtalk.com/forum/peptide-research-library/ghk-cu-kpv-research-monograph-copper-msh-fragment-stack
[5] GHK-Cu attenuates induced inflammation in zebrafish larvae (2026) — https://pubmed.ncbi.nlm.nih.gov/41997403/
[6] Mechanism of KPV action in human bronchial epithelial cells — https://pubmed.ncbi.nlm.nih.gov/22837805/
[7] A KPV-binding double-network hydrogel restores gut mucosal barrier in an inflamed colon — https://pubmed.ncbi.nlm.nih.gov/35245681/
[8] Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing (2025) — https://pubmed.ncbi.nlm.nih.gov/40789979/
[9] BPC 157 tendon healing: outgrowth, cell survival and migration (rat tendon fibroblasts) — https://pubmed.ncbi.nlm.nih.gov/21030672/
[10] BPC-157 and GHK-Cu in Wound Healing and Tissue Repair: A Review (2026) — https://doi.org/10.12775/qs.2026.54.70818
[11] Willis & Vu, Int J Pharm Compd 2026 — Synthetic Peptides in Pharmacy Compounding — https://pubmed.ncbi.nlm.nih.gov/42752426/
[12] Tewari et al., Am J Sports Med 2026 — Peptide Supplements in Sports Medicine — https://pubmed.ncbi.nlm.nih.gov/42578445/
[13] NCT07437586 — GHK-Cu skin gel for wounds (Phase 2, recruiting) — https://clinicaltrials.gov/study/NCT07437586
[14] NCT07437547 — BPC 157 for hamstring strain (Phase 2, recruiting) — https://clinicaltrials.gov/study/NCT07437547
Research-use note: This monograph is an educational summary of the published literature on GHK-Cu, KPV and BPC-157. The three-peptide combination has not been studied in any published human or animal experiment known to VialTalk, and neither KPV nor BPC-157 is an approved drug. Nothing here is medical advice or a usage recommendation.
